Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy

Journal of Child Neurology

Volumn 18, Issue 8, 2003, Pages 552-554

  Kurul, Semra ^a   Dirik, Eray ^a   İscan, Akin ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARNITINE; OXCARBAZEPINE;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; BLOOD ANALYSIS; BLOOD LEVEL; CARNITINE DEFICIENCY; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANK SUM TEST; SPECTROPHOTOMETRY;

ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; CARNITINE; CHILD; EPILEPSY; FEMALE; HUMANS; MALE;

EID: 0042884437     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180080201     Document Type: Article

References (19)

1. Hunt PA, Pellock JM: Carnitine deficiency. Pediatrics 1995;96:1176.
2. Haeckel R, Kaiser E, Oellerich M, Silprandi N: Carnitine: Metabolism, function and clinical application. J Clin Chem Clin Biochem 1990;28:291-295.
3. Tanphaichitr V, Leelahagul P: Carnitine metabolism and human carnitine deficiency. Nutrition 1993;9:246-255.
4. De Vivo DC, Tein I: Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5:134-141.
5. Shuper A, Gutman A, Mimouni M: Intractable epilepsy. Lancet 1999;353:1238.
6. Campistol J, Chavez B, Vilaseca MA, Artuch R: Antiepileptic drugs and carnitine. Rev Neurol 2000;30:105-109.
7. Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, et al: Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998;13:546-549.
8. Zelnik N, Fridkis I, Gruener N: Reduced carnitine and antiepileptic drugs: Cause relationship or coexistence? Acta Pediatr 1995;84:93-95.
9. Hiraoka A, Arato T, Tominaga I: Reduction in blood free carnitine levels in association with changes in serum valproate (VPA) disposition in epileptic patients treated with VPA and other antiepileptic drugs. Biol Pharm Bull 1997;20:91-93.
10. Verrotti A, Greco R, Morgese G, Chiarelli F: Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999; 29:36-40.
11. Can-dna MF, Rozas I, Castro-Gago M, et al: Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology 1991;41:1444-1448.
12. Hug G, McGraw CA, Bates SR, Landrigan EA. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991;119:799-802.
13. Ohtani Y, Endo F, Matsuda I: Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982;101:782-785.
14. Opala G, Winter S, Vance C, et al: The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991;145:999-1001.
15. Dichter MA, Brodie MJ: New antiepileptic drugs. N Engl J Med 1996;334:1523-1590.
16. Schafer J, Reichman H: A spectrophotometric method for the determination of free and esterified carnitine. Clin Chem Acta 1989;182:87-94.
17. Tein I, DiMauro S, Xie ZW, De Vivo DC: Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. J Inherit Metab Dis 1995; 18:313-322.
18. Melegh B, Pap M, Morava E, et al: Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr 1994;125:317-321.
19. Lloyd P, Flesch G, Dieterle W: Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(Suppl 3):S10-S13.